These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 20196721)

  • 1. New targets of therapy in T-cell lymphomas.
    Erter J; Alinari L; Darabi K; Gurcan M; Garzon R; Marcucci G; Bechtel MA; Wong H; Porcu P
    Curr Drug Targets; 2010 Apr; 11(4):482-93. PubMed ID: 20196721
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New drug therapies in peripheral T-cell lymphoma.
    Howman RA; Prince HM
    Expert Rev Anticancer Ther; 2011 Mar; 11(3):457-72. PubMed ID: 21417858
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting histone deacetyalses in the treatment of B- and T-cell malignancies.
    Zain J; O'Connor OA
    Invest New Drugs; 2010 Dec; 28 Suppl 1(Suppl 1):S58-78. PubMed ID: 21132350
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aurora A Kinase Inhibition Selectively Synergizes with Histone Deacetylase Inhibitor through Cytokinesis Failure in T-cell Lymphoma.
    Zullo KM; Guo Y; Cooke L; Jirau-Serrano X; Mangone M; Scotto L; Amengual JE; Mao Y; Nandakumar R; Cremers S; Duong J; Mahadevan D; O'Connor OA
    Clin Cancer Res; 2015 Sep; 21(18):4097-109. PubMed ID: 25878331
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel targeted therapies of T cell lymphomas.
    Iżykowska K; Rassek K; Korsak D; Przybylski GK
    J Hematol Oncol; 2020 Dec; 13(1):176. PubMed ID: 33384022
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic Options for Aggressive T-Cell Lymphomas.
    Lue JK; Kress A; Amengual JE
    Curr Hematol Malig Rep; 2017 Aug; 12(4):269-281. PubMed ID: 28573497
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel systemic drugs for cutaneous T-cell lymphoma.
    Lech-Maranda E; Robak E; Robak T
    Recent Pat Anticancer Drug Discov; 2011 Jan; 6(1):70-93. PubMed ID: 21110825
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The emerging role of histone deacetylase inhibitors in treating T-cell lymphomas.
    Horwitz SM
    Curr Hematol Malig Rep; 2011 Mar; 6(1):67-72. PubMed ID: 21080243
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting histone deacetylases in T-cell lymphoma.
    Moskowitz AJ; Horwitz SM
    Leuk Lymphoma; 2017 Jun; 58(6):1306-1319. PubMed ID: 27813438
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel agents in development for peripheral T-cell lymphoma.
    O'Connor OA
    Semin Hematol; 2010 Apr; 47 Suppl 1():S11-4. PubMed ID: 20359580
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of proteasome inhibitors in oncology and autoimmune diseases.
    Bennett MK; Kirk CJ
    Curr Opin Drug Discov Devel; 2008 Sep; 11(5):616-25. PubMed ID: 18729013
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular biology and targeted therapy of cutaneous T-cell lymphomas.
    Klemke CD; Goerdt S
    G Ital Dermatol Venereol; 2008 Dec; 143(6):365-74. PubMed ID: 19169209
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Histone deacetylase inhibitors downregulate CCR4 expression and decrease mogamulizumab efficacy in CCR4-positive mature T-cell lymphomas.
    Kitadate A; Ikeda S; Abe F; Takahashi N; Shimizu N; Matsue K; Tagawa H
    Haematologica; 2018 Jan; 103(1):126-135. PubMed ID: 29025909
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pralatrexate: an emerging new agent with activity in T-cell lymphomas.
    O'Connor OA
    Curr Opin Oncol; 2006 Nov; 18(6):591-7. PubMed ID: 16988580
    [TBL] [Abstract][Full Text] [Related]  

  • 15. From a Better Understanding of the Mechanisms of Action of Histone Deacetylases Inhibitors to the Progress of the Treatment of Malignant Lymphomas and Plasma Cell Myeloma.
    Mihaila RG
    Recent Pat Anticancer Drug Discov; 2017 Nov; 12(4):283-295. PubMed ID: 28933264
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HDAC inhibitors in cancer care.
    Tofilon PJ; Camphausen K
    Oncology (Williston Park); 2010 Feb; 24(2):180-5. PubMed ID: 20361469
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HDAC inhibitors for the treatment of cutaneous T-cell lymphomas.
    Rangwala S; Zhang C; Duvic M
    Future Med Chem; 2012 Mar; 4(4):471-86. PubMed ID: 22416775
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preclinical pharmacologic evaluation of pralatrexate and romidepsin confirms potent synergy of the combination in a murine model of human T-cell lymphoma.
    Jain S; Jirau-Serrano X; Zullo KM; Scotto L; Palermo CF; Sastra SA; Olive KP; Cremers S; Thomas T; Wei Y; Zhang Y; Bhagat G; Amengual JE; Deng C; Karan C; Realubit R; Bates SE; O'Connor OA
    Clin Cancer Res; 2015 May; 21(9):2096-106. PubMed ID: 25677697
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emerging therapies in multiple myeloma.
    El-Amm J; Tabbara IA
    Am J Clin Oncol; 2015 Jun; 38(3):315-21. PubMed ID: 23934133
    [TBL] [Abstract][Full Text] [Related]  

  • 20. T time: Emerging and new therapies for peripheral T-cell lymphoma.
    Mina A; Pro B
    Blood Rev; 2022 Mar; 52():100889. PubMed ID: 34716031
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.